Cellectis SA (FR:ALCLS)
:ALCLS
Top Page
Cellectis SA
(ALCLS)
Select Model
Select Model
Rating:44Neutral
Price Target:
€3.00
▼(-22.28% Downside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial performance: despite a sharp revenue rebound and strong gross margin, large operating/net losses, renewed cash burn, and a weakening balance-sheet trend (higher leverage, lower equity) increase risk. Technicals remain negative with the stock below key moving averages and a negative MACD, with oversold signals offering only limited offset. Valuation provides little support given the negative P/E and no dividend yield data.
Positive Factors
Proprietary gene-editing platform
Cellectis' proprietary gene‑editing platform and focus on allogeneic (off‑the‑shelf) CAR‑T creates a structural competitive advantage. A scalable, platform-based approach can lower per‑patient cost, enable multiple programs from shared tech, and attract long-term partner investment.
Negative Factors
Large persistent operating and net losses
Sustained large operating and net losses reflect heavy, ongoing R&D and G&A burn. Over time this erodes equity, increases dependence on external financing or dilutive raises, and limits ability to self‑fund pivotal trials or scale commercial capabilities without partners or debt.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary gene-editing platform
Cellectis' proprietary gene‑editing platform and focus on allogeneic (off‑the‑shelf) CAR‑T creates a structural competitive advantage. A scalable, platform-based approach can lower per‑patient cost, enable multiple programs from shared tech, and attract long-term partner investment.
Read all positive factors
Cellectis SA (ALCLS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€208.88M
Dividend YieldN/A
Average Volume (3M)852.48K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue Growth150.80%
EPS Growth67.81%
CountryFR
Employees216
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.23
Shares Outstanding72,325,455
10 Day Avg. Volume1,338,181
30 Day Avg. Volume852,477
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.88
Revenue Forecast (FY)€54.75M
Cellectis SA Business Overview & Revenue Model
Company Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics ...
How the Company Makes Money
Cellectis primarily generates revenue through (1) collaboration and licensing arrangements and (2) research-and-development related payments from partners, rather than from product sales, since it is a clinical-stage company and does not have broa...
Cellectis SA Earnings Call Summary
Earnings Call Date:Aug 04, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.Positive Updates
Initiation of Pivotal Phase II Trial for lasme-cel
Cellectis is preparing to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Negative Updates
Servier Arbitration
Cellectis is engaged in arbitration with Servier regarding the termination of a licensing agreement, seeking compensation for losses due to lack of development of licensed products. The decision is expected by December 15, 2025.
Read all updates
Q2-2025 Updates
Positive
Negative
Initiation of Pivotal Phase II Trial for lasme-cel
Cellectis is preparing to initiate the pivotal Phase II trial for lasme-cel (UCART22) in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Read all positive updates
Company Guidance
During Cellectis' Second Quarter 2025 Earnings Call, the company provided guidance on several key metrics. They announced the completion of end-of-Phase I discussions with the FDA and EMA for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia, and their preparation to initiate a pivotal Phase II trial in the second half of 2025. Additionally, the NatHaLi-01 study on UCART20x22 is progressing, with Phase I data anticipated by late 2025. Cellectis is advancing three cell and gene therapy programs under their partnership with AstraZeneca. Financially, the company reported cash, cash equivalents, and fixed-term deposits of $230 million as of June 30, 2025, which are expected to fund operations into the second half of 2027. They are also involved in arbitration with Servier, with a decision expected by December 15, 2025. The company will provide further insights and data during their Investor R&D Day on October 16, 2025.Cellectis SA Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
41
Neutral
Cash Flow
38
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 75.92M | 41.51M | 755.00K | 19.17M | 73.95M |
| Gross Profit | 55.04M | 41.51M | 18.00K | 17.40M | 37.67M |
| EBITDA | -21.12M | -9.46M | -92.64M | -76.38M | -85.44M |
| Net Income | -70.35M | -36.76M | -101.06M | -98.69M | -86.28M |
Balance Sheet | |||||
| Total Assets | 324.76M | 383.54M | 334.27M | 261.22M | 382.08M |
| Cash, Cash Equivalents and Short-Term Investments | 208.69M | 260.31M | 203.81M | 97.70M | 186.13M |
| Total Debt | 119.91M | 91.46M | 85.06M | 82.85M | 102.24M |
| Total Liabilities | 248.85M | 252.51M | 249.57M | 135.28M | 145.60M |
| Stockholders Equity | 75.91M | 131.03M | 84.69M | 117.97M | 221.29M |
Cash Flow | |||||
| Free Cash Flow | -44.10M | 19.15M | -25.82M | -89.89M | -124.31M |
| Operating Cash Flow | -41.64M | 22.99M | -24.75M | -87.44M | -104.56M |
| Investing Cash Flow | -30.69M | -102.81M | -15.51M | -2.76M | 7.28M |
| Financing Cash Flow | -16.81M | 89.11M | 82.86M | 1.15M | 47.52M |
Cellectis SA Technical Analysis
Negative
3.86
Price Trends
3.21
Negative
3.56
Negative
3.04
Negative
Market Momentum
-0.10
Negative
42.39
Neutral
66.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Negative. The current price of 3.86 is above the 20-day moving average (MA) of 3.04, above the 50-day MA of 3.21, and above the 200-day MA of 3.04, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 42.39 is Neutral, neither overbought nor oversold. The STOCH value of 66.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCLS.
Cellectis SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | €1.24B | -38.59 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €208.17M | -2.10 | -634.16% | ― | 111.76% | -22.45% | |
49 Neutral | €68.46M | -1.87 | -52.76% | ― | -96.92% | -175.84% | |
46 Neutral | €103.50M | -2.91 | -658.91% | ― | -75.86% | -30.54% | |
45 Neutral | €101.84M | -1.20 | ― | ― | 52.55% | -5.97% | |
44 Neutral | €208.88M | -7.03 | -30.75% | ― | 150.80% | 67.81% |
* Healthcare Sector Average
FR:ALCLS
Cellectis SA
2.89
1.76
156.48%
FR:IPH
Innate Pharma SA
1.10
-0.55
-33.17%
FR:NANO
Nanobiotix
25.62
22.73
786.81%
FR:TNG
Transgene
0.76
0.15
24.18%
FR:OSE
OSE Immunotherapeutics SA
3.05
-2.10
-40.74%
FR:MAAT
MaaT Pharma
5.41
-0.69
-11.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.